Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-09-10
DOI
10.3389/fonc.2019.00887
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics
- (2019) Jerry Harb et al. Current Oncology Reports
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo
- (2019) Ning Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
- (2019) Owen A. O’Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- AICAr suppresses cell proliferation by inducing NTP and dNTP pool imbalances in acute lymphoblastic leukemia cells
- (2019) Lijuan Du et al. FASEB JOURNAL
- Sintilimab: First Global Approval
- (2019) Sheridan M. Hoy DRUGS
- Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib
- (2019) CHING-TING WEI et al. ANTICANCER RESEARCH
- FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4
- (2019) Lana McClements et al. BMC CANCER
- Matrix stiffening and EGFR cooperate to promote the collective invasion of cancer cells.
- (2018) Eloise M Grasset et al. CANCER RESEARCH
- HALO-109–301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer
- (2018) Gary J Doherty et al. Future Oncology
- A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
- (2018) Hideki Ueno et al. INVESTIGATIONAL NEW DRUGS
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
- (2018) Laura Graham et al. INVESTIGATIONAL NEW DRUGS
- Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells
- (2018) Hauke Löcken et al. JOURNAL OF NATURAL PRODUCTS
- Strategies to target the Hedgehog signaling pathway for cancer therapy
- (2018) Minhang Xin et al. MEDICINAL RESEARCH REVIEWS
- A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
- (2018) Anthony Tolcher et al. ONCOLOGIST
- Buparlisib is a brain penetrable pan-PI3K inhibitor
- (2018) Mark C. de Gooijer et al. Scientific Reports
- Hedgehog Signaling Pathway and Autophagy in Cancer
- (2018) Xian Zeng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation
- (2018) Su Myat Phyu et al. INVESTIGATIONAL NEW DRUGS
- Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
- (2018) Hassan Dianat-Moghadam et al. JOURNAL OF CONTROLLED RELEASE
- 410OFirst-in-human, first-in-class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors
- (2018) E Calvo et al. ANNALS OF ONCOLOGY
- Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
- (2018) Greg P. Coffey et al. CLINICAL CANCER RESEARCH
- Design of Hedgehog pathway inhibitors for cancer treatment
- (2018) Jitender Bariwal et al. MEDICINAL RESEARCH REVIEWS
- Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation
- (2018) Vijay Pandey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A role for paracrine interleukin‐6 signaling in the tumor microenvironment in prostate tumor growth
- (2018) Shu‐Han Yu et al. PROSTATE
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
- (2018) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- The Role of PDGFs and PDGFRs in Colorectal Cancer
- (2017) Roberta M. Manzat Saplacan et al. MEDIATORS OF INFLAMMATION
- Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
- (2017) Katherine M. Morgan et al. MOLECULAR CANCER THERAPEUTICS
- β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma
- (2017) Ioanna Savvidou et al. MOLECULAR CANCER THERAPEUTICS
- Cancer stem cells revisited
- (2017) Eduard Batlle et al. NATURE MEDICINE
- Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)
- (2017) Kit Man Wong et al. Current Oncology Reports
- A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
- (2016) Vicky Makker et al. CANCER
- CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α
- (2016) Xi Tian et al. CANCER RESEARCH
- The relationship between vasculogenic mimicry and epithelial-mesenchymal transitions
- (2016) Qiqi Liu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Epithelial–mesenchymal transition: a new target in anticancer drug discovery
- (2016) Fabrizio Marcucci et al. NATURE REVIEWS DRUG DISCOVERY
- WP1066 exhibits antitumor efficacy in nasal-type natural killer/T-cell lymphoma cells through downregulation of the STAT3 signaling pathway
- (2016) Lingyun Geng et al. ONCOLOGY REPORTS
- Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
- (2016) Norbert Vey et al. Oncotarget
- Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)
- (2015) Mario E. Lacouture et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathway
- (2015) Xiao Liu et al. CANCER SCIENCE
- Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
- (2015) CLINICAL CANCER RESEARCH
- Sonidegib: First Global Approval
- (2015) Celeste B. Burness DRUGS
- Advanced research on vasculogenic mimicry in cancer
- (2015) Lili Qiao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
- (2015) Koji Sasaki et al. LEUKEMIA & LYMPHOMA
- Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors
- (2015) Filip Janku et al. MOLECULAR CANCER THERAPEUTICS
- Wnt addiction of genetically defined cancers reversed by PORCN inhibition
- (2015) B Madan et al. ONCOGENE
- Epithelial–Mesenchymal Plasticity: A Central Regulator of Cancer Progression
- (2015) Xin Ye et al. TRENDS IN CELL BIOLOGY
- Panobinostat for the treatment of multiple myeloma
- (2015) Minal Surati et al. Expert Opinion on Orphan Drugs
- Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
- (2015) Yi Yu et al. PLoS One
- Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
- (2014) Kodappully Sivaraman Siveen et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
- (2014) N. Mimura et al. CANCER RESEARCH
- Sonidegib phosphate: Smoothened (SMO) receptor antagonist oncolytic
- (2014) M. Salati et al. DRUGS OF THE FUTURE
- LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: Application to a pharmacokinetic study
- (2014) Lihua He et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth
- (2014) V. T. Campbell et al. MOLECULAR CANCER THERAPEUTICS
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- (2014) John C. Morris et al. PLoS One
- Activation of Mesenchymal Stem Cells by Macrophages Prompts Human Gastric Cancer Growth through NF-κB Pathway
- (2014) Tingting Yang et al. PLoS One
- Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1
- (2014) B. Faubert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crosstalk with Cancer-Associated Fibroblasts Increases the Growth and Radiation Survival of Cervical Cancer Cells
- (2014) Tang-Yuan Chu et al. RADIATION RESEARCH
- LIF Mediates Proinvasive Activation of Stromal Fibroblasts in Cancer
- (2014) Jean Albrengues et al. Cell Reports
- Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery
- (2013) H. Shen et al. CLINICAL CANCER RESEARCH
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
- (2013) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Denosumab in breast cancer treatment
- (2013) Jan C. Drooger et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
- (2013) J. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the NF-κB Pathway in Cancer Therapy
- (2013) Derek J. Erstad et al. Surgical Oncology Clinics of North America
- Of plasticity and specificity: dialectics of the microenvironment and macroenvironment and the organ phenotype
- (2013) Ramray Bhat et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis
- (2012) Carmen Chak-Lui Wong et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Matrix rigidity regulates a switch between TGF-β1–induced apoptosis and epithelial–mesenchymal transition
- (2012) Jennifer L. Leight et al. MOLECULAR BIOLOGY OF THE CELL
- Vismodegib
- (2012) Andrzej Dlugosz et al. NATURE REVIEWS DRUG DISCOVERY
- Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs
- (2011) Qing Chen et al. CANCER CELL
- ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy
- (2010) Xi-wei Ding et al. LIFE SCIENCES
- LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling
- (2010) Y. Gao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways
- (2008) T. T. Onder et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started